Shimadzu debuts two new ultrasound systems
Displayed in 1999 as a work-in-progress, Shimadzu's SDU-2200 will be shown as a finished product at this year's RSNA meeting. A new version of the SDU-450, the SDU-450 XL, will also be introduced.The SDU-2200 system includes 3-D, tissue harmonic imaging,
Displayed in 1999 as a work-in-progress, Shimadzu's SDU-2200 will be shown as a finished product at this year's RSNA meeting. A new version of the SDU-450, the SDU-450 XL, will also be introduced.
The SDU-2200 system includes 3-D, tissue harmonic imaging, and DICOM connectivity. Its proprietary digital electronics provide high-speed parallel processing, a quad digital beamformer, and high-level digital noise suppression. The SDU-2200 is a multipurpose, shared services system with applications that include cardiac, vascular, abdominal, ob/gyn, and urology.
The SDU-1200 uses the same console, operating system, and digital electronics as the SDU-2200. Applications are vascular, abdominal, ob/gyn, and urology, and its intended markets are outpatient centers and large private practices.
Both systems are semiautomatic and suitable for mobile applications.
The new SDU-450 XL includes an upgraded CPU with faster processing and enhanced applications software for ob/gyn, urology, emergency medicine, and family practice.
Shimadzu Ultrasound systems include Shimadzu's Truevision broadband probe technology with frequency versatility of 2 to 15 MHz.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
